Pfizer readies to compete against Ascendis and Novo Nordisk: Submits weekly growth hormone to FDA

The US FDA has started processing a week-based growth hormone from partners Pfizer and Opko, which will compete against new drugs from Novo Nordisk and Ascendis.

Danish pharmaceutical companies Novo Nordisk and Ascendis have renewed competition to look forward to in the market for treating dwarfism.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must contain at least 6 characters
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading